CDRD, Canada’s national Centre for Drug Research and Development, is a global bridge that translates discoveries into innovative therapeutic products & improved health outcomes. In collaboration with our partners, we identify & advance promising discoveries & transform them into validated investments – all while uniquely training the next generation of highly-qualified personnel to drive the development of the innovations of tomorrow.
Scroll down to find out how we do this...
Identify & Evaluate
We proactively identify and evaluate
therapeutically promising and commercially relevant early-stage technologies within academia and Canadian life sciences companies.
Validate & Incubate
We replicate data, and build interdisciplinary
teams of experts to define and execute critical
experiments that will maximize probability of future clinical success and attract capital.
Accelerate & Commercialize
We generate valuable data around a technology, build a compelling business case and
comprehensive intellectual property package, and secure the private sector investors / partners to take the technology to patients.
October 17, 2017
Thank you for your ongoing commitment to CDRD. This purpose of this note is to celebrate our successes and report to you on what we have in store....Top global translational science organizations to catalyze...Read MoreInvest in BCRead More
Top global translational science organizations to catalyze translational innovation through new initiative – Translation TogetherSeptember 25, 2017
Five of the world’s top translational science organizations representing the European Union, the United Kingdom, the United States, Canada, and Australia have joined forces under the new banner of Translation Together. This new collaboration will enable the leveraging of complementary scientific and operational strengths of member...CDRD Launches New Video Series Featuring Tomorrow’s...Read MoreFall Greetings to CDRD StakeholdersRead More
September 24, 2017
A key part of CDRD’s Mission is training the next generation of highly-qualified personnel to drive the development of new innovations. Visit our YouTube Channel to meet some of the impressive young CDRD scientists poised to take on that role....JDRF Funds Zucara Therapeutics’ Approach to Preventing...Read MoreTop global translational science organizations to catalyze...Read More
September 21, 2017
JDRF is pleased to announce that it will contribute funding to Canada’s Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel therapeutic approach to prevent hypoglycemia in patients with diabetes....Sepset Biosciences Initiates Multicenter Human Clinical...Read MoreCDRD Launches New Video Series Featuring Tomorrow’s...Read More
September 13, 2017
Vancouver, BC: Marking World Sepsis Day, Sepset Biosciences Inc., announces the commencement of a multi-country, multi-center human clinical study that will validate and refine Sepset’s proprietary gene signature to quickly and accurately identify patients with sepsis. A spin-out of The Centre for Drug Research and Development...LifeArc, Dstl & CDRD Collaborate to Identify...Read MoreJDRF Funds Zucara Therapeutics’ Approach to Preventing...Read More
June 27, 2017
LifeArc, CDRD, and the Defence Science and Technology Laboratory (Dstl), today announced a collaboration to identify antibacterial drug targets....CDRD Spin-Off Sitka Biopharma to Start Clinical Trials of ...Read MoreSepset Biosciences Initiates Multicenter Human Clinical...Read More
June 26, 2017
Vancouver, BC and London, UK: An experimental treatment for bladder cancer will move into an early phase clinical trial under an agreement signed today between Cancer Research UK and Cancer Research Technology (CRT), the charity’s commercial arm, and Canadian biotechnology company Sitka Biopharma Inc., a spin-off...Aequus Pharmaceuticals & CDRD Announce Research...Read MoreLifeArc, Dstl & CDRD Collaborate to Identify...Read More
Aequus Pharmaceuticals & CDRD Announce Research Collaboration to Improve Cannabinoid-based TherapeuticsJune 1, 2017
Vancouver, BC: Today Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) a specialty pharmaceutical company with expertise in drug delivery and clinical development, and the Centre For Drug Research and Development (“CDRD”), Canada’s national drug development and commercialization centre, announced a broad research collaboration to establish...New Progressive MS Translational Research Project LaunchedRead MoreCDRD Spin-Off Sitka Biopharma to Start Clinical Trials of ...Read More
May 31, 2017
MS Society of Canada continues collaboration with the Centre for Drug Research and Development as new translational project on progressive MS is launched / La Société canadienne de la sclérose en plaques poursuit sa collaboration avec le Centre de recherche et développement des médicaments à l’occasion...Aequus Pharmaceuticals & CDRD Announce Research...Read More
May 16, 2017
Today the CDRD staff welcomed four new Aboriginal students to our headquarters for an intensive week of science training and mentorship. From May 15-19 Amber Chief-stick-Rowan, Katrina Boysis from Pigeon Lake, AB, Lucas McCreery from Rorketon, MB and Destiny Anderson from Gift Lake, AB will join...Fall Greetings to CDRD StakeholdersRead More
Zucara Therapeutics Inc. is pleased to announce that Mr. Luc Mainville has been appointed Chair of its Board of Directors....Read the article
Outcomes with Impact
September 19, 2017
CDRD is committed to training the next generation of highly-qualified personnel to drive the development of innovations. Hear more about our unique Training Program and the opportunities it is creating from some of our young scientists…....Novel therapies advancedRead More
August 24, 2017
CDRD has advanced 58 potential novel drug therapies towards the clinic. Many more are in production....Commercial transactionsRead MoreTraining the Next GenerationRead More
August 11, 2017
CDRD has completed 14 commercial transactions including the merger of CDRD spin-off company, Kairos Therapeutics, with BC-based Zymeworks Inc. and creating one of Canada’s leading biotherapeutics companies....Spin-off CompaniesRead MoreNovel therapies advancedRead More
August 11, 2017
CDRD has successfully created 7 spin-off companies including Kairos Therapeutics, Sitka Biopharma, Zucara Therapeutics, Precision Nanosystems, Immcure Therapeutics, Mesentech and Sepset Biopharma....Commercial transactionsRead More
Working with CDRD
Academic discovery is the watering hole of innovation, but developing discoveries into new therapeutic products is a challenging process that requires complementary expertise, infrastructure and resources to that typically available to an investigator. That's where CDRD comes in.
Whether a company is looking to accelerate development of their lead program or strengthen their pipeline by pulling a secondary program off the back-burner, CDRD provides solutions for whatever scientific and/or commercial roadblocks are impeding progress towards the next corporate value-creation point.